{"denoms":[{"counts":[{"groupId":"BG000","value":"26"}],"units":"Participants"}],"groups":[{"description":"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.\n\nPatients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression.","id":"BG000","title":"Treatment (Cisplatin, Triapine, Radiation Therapy)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"30-39"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"40-49"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"50-59"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"60-69"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"70-79"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"18"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"1"}],"description":"One patient was non-compliant and received no therapy. Patient was excluded from study specific baseline characteristics. The Gynecologic Oncology Group (GOG) performance status reflects individual daily living activities on a scale of 0 (fully active with symptoms) to 5 (dead).","paramType":"NUMBER","title":"GOG Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"Squamous cell carcinoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Adenosquamous carcinoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Adenocarcinoma"}],"description":"One patient was non-compliant and received no therapy. Patient was excluded from study specific baseline characteristics.","paramType":"NUMBER","title":"Histopathology","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Grade 3"}],"description":"One patient was non-compliant and received no therapy. Patient was excluded from study specific baseline characteristics.","paramType":"NUMBER","title":"Tumor Grade","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Less than 2/3rds invasion"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"2/3rds or greater invasion"}],"description":"One patient was non-compliant and received no therapy. Patient was excluded from study specific baseline characteristics.","paramType":"NUMBER","title":"Cervical Stromal Invasion","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Absent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"title":"Present"}],"description":"One patient was non-compliant and received no therapy. Patient was excluded from study specific baseline characteristics.","paramType":"NUMBER","title":"Lymphovascular invasion","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Cervix IB2 Node Negative"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Cervix IB2 Node Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Cervix IIA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Cervix IIB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Cervix IIIB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Cervix IVB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Vagina II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Vagina IVA"}],"description":"One patient was non-compliant and received no therapy. Patient was excluded from study specific baseline characteristics.","paramType":"NUMBER","title":"International Federation of Gynecology and Obstetrics (FIGO) Stage","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"HPV 16"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"HPV 18"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"HPV-naive"}],"description":"Cervical cancer genotyping","paramType":"NUMBER","title":"HPV Genotyping","unitOfMeasure":"participants"}],"populationDescription":"Baseline demographic characteristics include all 26 patients. Study specific characteristics only include the 25 patients that received treatment."}